Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Luitpold Pharma takes over Roxro Pharma
Roxro Pharma obtained FDA approval for Sprix (ketorolac tromethamine) nasal spray in May of 2010, for the short-term (up to 5 days) management of acute moderate to moderately
Roxro Pharma obtained FDA approval for Sprix (ketorolac tromethamine) nasal spray in May of 2010, for the short-term (up to 5 days) management of acute moderate to moderately
NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar’s lead oncology candidate and is being evaluated in multiple cancer indications. The randomised Phase 2 study evaluated two
The double-blind, randomised, placebo-controlled Phase I will enroll up to 72 healthy adult volunteers and is designed to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of
MorphoSys claims that Sloning’s Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre- determined positions with unprecedented speed. The MorphoSys
Treakisym is the first anticancer agent for Eisai to launch in Japan, and although it is already available in the US. Eisai claims that Treakisym is a novel
Nifedipine is a drug belonging to a class of pharmacological agents known as the calcium channel blockers that affects the amount of calcium found in the heart and
Dotmatics is a provider of informatics tools and scientific data management solutions to the international pharmaceutical and biotechnology industries. Dotmatics CEO Stephen Gallagher said they have enjoyed an
THG provides global payer research, strategic planning and global value dossiers for biopharmaceutical products. THG, together with UBC’s existing value strategy and research services, will be led by
A large pharma firm can have tens or hundreds of thousands of employees in offices all around the globe; furthermore, there is the sheer variety of different departments
Dasatinib, an oral BCR-ABL inhibitor, was initially approved in November 2006 by the European Commission for the treatment of adults for all phases of CML (chronic, accelerated, or